Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$379.90
+99.35% vs spot
Strong Buy
Spot price
$190.57
Mkt cap $27.64B
subtle cardAnalyst PT consensus
$281.29
+47.60% vs spot
subtle cardMethods covered
18 / 19
15 in blend
subtle cardFootball field
RMD · fair-value range by method
Method comparison
RMD · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $769.79 | $480.22 – $1,477.09 | +303.94% | 22.3% | WACC 7.3%, g₀=17.3%, gₗ=4.9% | high |
| DCF · FCFE | dcf | $557.95 | $376.50 – $909.70 | +192.78% | 16.8% | kₑ 8.2%, g₀=17.3%, gₗ=4.9% | high |
| DDM · Gordon | ddm | $61.76 | $47.62 – $87.84 | -67.59% | — | D₁ 1.98, kₑ 8.2%, gₗ 4.9% | med |
| DDM · H-model | ddm | $98.45 | $69.10 – $152.59 | -48.34% | — | D₀ 1.98, g₀=17.3%, gₗ=4.9%, H 5y | med |
| DDM · multi-stage | ddm | $81.42 | $69.20 – $93.63 | -57.28% | 5.6% | 5y schedule 17.3% → 4.9%, kₑ 8.2% | high |
| Residual income | income | $52.58 | $46.27 – $58.89 | -72.41% | 11.2% | BV 38.08, ROE 23.5% → kₑ | high |
| EVA / MVA | income | $483.26 | $425.27 – $541.25 | +153.59% | 7.8% | IC 5.6B, WACC 7.3% | high |
| P/E · sector | multiple | $209.22 | $184.11 – $234.33 | +9.79% | 13.4% | EPS 9.51 × peer P/E 22.0 | med |
| P/S · sector | multiple | $131.35 | $111.65 – $151.05 | -31.08% | 3.4% | Rev/sh 32.84 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $185.41 | $163.16 – $207.66 | -2.71% | 11.2% | EBITDA × peer 15.0× − ND -0.4B | high |
| EV / EBIT | multiple | $195.85 | $166.47 – $225.23 | +2.77% | 2.2% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $113.93 | $96.84 – $131.02 | -40.22% | 2.2% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $159.82 | $135.85 – $183.80 | -16.13% | 1.1% | PEG=1, fwd EPS g 16.8% | med |
| Earnings power | intrinsic | $119.12 | $104.82 – $133.41 | -37.49% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $404.74 | $344.03 – $465.45 | +112.38% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $164.71 | $140.01 – $189.42 | -13.57% | 0.6% | PE = g (17.3) | low |
| Book NAV | asset | $38.08 | $36.17 – $39.98 | -80.02% | 1.1% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $24.75 | $21.03 – $28.46 | -87.01% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g -15.0% · Pessimistic — market pricing decline | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (0.84)β | × 0.84 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 8.23% |
| Pre-tax cost of debtkd | 1.48% |
| Effective tax ratet | 20.2% |
| After-tax cost of debt | 1.18% |
| Equity weight$6.0B | 87.5% |
| Debt weight$0.9B | 12.5% |
| WACC | 7.35% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 9.80% |
| Analyst forward EPS growthFMP | 16.81% |
| Historical 5y revenue CAGRFY | 12.64% |
| Historical 5y EPS CAGRFY | 30.89% |
| Sustainable g (ROE × retention)Δ | 18.26% |
| Blended near-term growth (g₀) | 17.32% |
| Terminal growth (gₗ) | 4.86% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-06-29)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $281.29
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.